GlycoMimetics Files 8-K on Operations

Ticker: CBIO · Form: 8-K · Filed: May 6, 2024 · CIK: 1253689

Glycomimetics INC 8-K Filing Summary
FieldDetail
CompanyGlycomimetics INC (CBIO)
Form Type8-K
Filed DateMay 6, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: operations, financial-condition, sec-filing

Related Tickers: GLYC

TL;DR

GlycoMimetics filed an 8-K on May 6th. Standard financial and operational update.

AI Summary

GlycoMimetics, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This filing indicates GlycoMimetics is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor company performance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of operational and financial information, not indicating any immediate adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on GlycoMimetics, Inc.'s results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on May 6, 2024.

What is the principal executive office address for GlycoMimetics, Inc.?

The address of GlycoMimetics, Inc.'s principal executive offices is 9708 Medical Center Drive, Rockville, MD 20850.

What is the telephone number for GlycoMimetics, Inc.?

The telephone number for GlycoMimetics, Inc. is (240) 243-1201.

What is the state of incorporation for GlycoMimetics, Inc.?

GlycoMimetics, Inc. is incorporated in Delaware.

Filing Stats: 786 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-05-06 16:01:01

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On May 6, 2024, GlycoMimetics, Inc. (the " Company ") issued a press release announcing, in addition to the information described in Item 7.01 below, its financial results for the first quarter ended March 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Topline Results from Phase 3 Clinical Trial On May 6, 2024, the Company issued a press release announcing, in addition to the information described in Item 2.02 above, topline results from its pivotal Phase 3 clinical trial of its drug candidate uproleselan in patients with relapsed/refectory acute myeloid leukemia. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Updated Corporate Presentation A copy of a slide presentation that the Company plans to use for anticipated investor meetings is attached to this Current Report as Exhibit 99.2 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 9, Exhibit Number Exhibit Description 99.1 Press Release, dated May 6, 2024, "GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)" 99.2 GlycoMimetics, Inc. Corporate Presentation, May 6, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. By: /s/ Brian M. Hahn Date: May 6, 2024 Brian M. Hahn Senior Vice President and Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing